Bad Blood: The Amgen/J&J Feud Takes a Perilous Turn

This article was originally published in RPM Report

01 Dec 2006
Analysis

Ramsey Baghdadi @Ramsey_Baghdadi ramsey.baghdadi@previsionpolicy.com

Executive Summary

The longstanding feud between Amgen and Johnson & Johnson is bubbling over into a battle of bundled rebates. The fight carries broad repercussions for the pricing of biopharmaceuticals. The dispute threatens to compromise the new ASP payment system under Medicare Part B before it really gets going. Industry observers threat that the next step may be more direct price controls.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Strategy Business Strategies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS079993

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS079993

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Bad Blood: The Amgen/J&J Feud Takes a Perilous Turn

Analysis

Executive Summary

Related Content

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert